These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Urinary epidermal growth factor excretion and breast cancer risk. Wang DY; Mockridge CI; Fantl VE; de Stavola B; Allen DS; Thomas BS; Moore JW; Bulbrook RD; Gravelle IH; Kwa HG Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1049-53. PubMed ID: 3261690 [TBL] [Abstract][Full Text] [Related]
7. Human urinary epidermal growth factor: effects of age, sex and pregnancy. Kasai K; Nakamura T; Banba N; Ishikawa M; Konuma S; Shimoda S Horm Res; 1989; 31(4):157-62. PubMed ID: 2793071 [TBL] [Abstract][Full Text] [Related]
8. [Measurement of urinary epidermal growth factor by radioimmunoassay and its application]. Fuse H; Mizuno I; Kurimoto F; Horiuchi J; Katayama T Nihon Naibunpi Gakkai Zasshi; 1991 May; 67(5):587-96. PubMed ID: 1868919 [TBL] [Abstract][Full Text] [Related]
9. [Prognostic value of urinary levels of corticosteroids and catecholamines in patients with cancer of the transverse colon and rectum]. Tarutinov VI; Kononenko VI Vopr Onkol; 1987; 33(5):48-54. PubMed ID: 3035800 [TBL] [Abstract][Full Text] [Related]
10. Urinary epidermal growth factor levels in patients with acute renal failure. Taira T; Yoshimura A; Iizuka K; Iwasaki S; Ideura T; Koshikawa S Am J Kidney Dis; 1993 Nov; 22(5):656-61. PubMed ID: 8238010 [TBL] [Abstract][Full Text] [Related]
12. Urinary pseudouridine/creatinine ratio as an indicator of gastrointestinal cancer. Higley B; De Mello J; Oakes DJ; Giles GR Br J Surg; 1982 Dec; 69(12):699-701. PubMed ID: 7171969 [TBL] [Abstract][Full Text] [Related]
13. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. Chen P; Cameron R; Wang J; Vallis KA; Reilly RM J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194 [TBL] [Abstract][Full Text] [Related]
14. Maturational changes and origin of urinary human epidermal growth factor in the neonatal period. Watanabe K; Ono A; Hirata Y; Fukuda Y; Kojima T; Kobayashi Y Biol Neonate; 1989; 56(5):241-5. PubMed ID: 2605276 [TBL] [Abstract][Full Text] [Related]
15. Assessment by a two-site enzyme immunoassay of human epidermal growth factor (urogastrone) in the urine of patients with various gastrointestinal diseases including malignant tumors. Kurobe M; Aono M; Moriga M; Furukawa S; Hayashi K Biochem Int; 1985 Dec; 11(6):817-23. PubMed ID: 3937528 [TBL] [Abstract][Full Text] [Related]
17. Human brain tumor-associated urinary high molecular weight transforming growth factor: a high molecular weight form of epidermal growth factor. Stromberg K; Hudgins WR; Dorman LS; Henderson LE; Sowder RC; Sherrell BJ; Mount CD; Orth DN Cancer Res; 1987 Feb; 47(4):1190-6. PubMed ID: 3026622 [TBL] [Abstract][Full Text] [Related]
18. Purification of a high molecular weight form of epidermal growth factor from urine of breast cancer patients. Eckert K; Granetzny A; Fischer J; Grosse R Biomed Biochim Acta; 1989; 48(1):111-20. PubMed ID: 2789043 [TBL] [Abstract][Full Text] [Related]
19. Urinary transforming growth factors in neoplasia: separation of 125I-labeled transforming growth factor-alpha from epidermal growth factor in human urine. Stromberg K; Hudgins WR Cancer Res; 1986 Nov; 46(11):6004-10. PubMed ID: 3019543 [TBL] [Abstract][Full Text] [Related]
20. Human epidermal growth factor in gastric carcinoma as a biologic marker of high malignancy. Tahara E; Sumiyoshi H; Hata J; Yasui W; Taniyama K; Hayashi T; Nagae S; Sakamoto S Jpn J Cancer Res; 1986 Feb; 77(2):145-52. PubMed ID: 2420773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]